Blennow K - Search Results

1

Sex-specific genetic predictors of Alzheimer's disease biomarkers.

Deming Y, Dumitrescu L, Barnes LL, Thambisetty M, Kunkle B, Gifford KA, Bush WS, Chibnik LB, Mukherjee S, De Jager PL, Kukull W, Huentelman M, Crane PK, Resnick SM, Keene CD, Montine TJ, Schellenberg GD, Haines JL, Zetterberg H, Blennow K, Larson EB, Johnson SC, Albert M, Moghekar A, Del Aguila JL, Fernandez MV, Budde J, Hassenstab J, Fagan AM, Riemenschneider M, Petersen RC, Minthon L, Chao MJ, Van Deerlin VM, Lee VM, Shaw LM, Trojanowski JQ, Peskind ER, Li G, Davis LK, Sealock JM, Cox NJ; Alzheimer’s Disease Neuroimaging Initiative (ADNI); Alzheimer Disease Genetics Consortium (ADGC); Goate AM, Bennett DA, Schneider JA, Jefferson AL, Cruchaga C, Hohman TJ. Deming Y, et al. Among authors: blennow k. Acta Neuropathol. 2018 Dec;136(6):857-872. doi: 10.1007/s00401-018-1881-4. Epub 2018 Jul 2. Acta Neuropathol. 2018. PMID: 29967939 Free PMC article.

2

Blood-brain barrier disturbance in patients with Alzheimer's disease is related to vascular factors.

Blennow K, Wallin A, Fredman P, Karlsson I, Gottfries CG, Svennerholm L. Blennow K, et al. Acta Neurol Scand. 1990 Apr;81(4):323-6. doi: 10.1111/j.1600-0404.1990.tb01563.x. Acta Neurol Scand. 1990. PMID: 2360400

3

Cerebrospinal fluid apolipoprotein E is reduced in Alzheimer's disease.

Blennow K, Hesse C, Fredman P. Blennow K, et al. Neuroreport. 1994 Dec 20;5(18):2534-6. doi: 10.1097/00001756-199412000-00032. Neuroreport. 1994. PMID: 7696597

4

Ubiquitin in cerebrospinal fluid in Alzheimer's disease and vascular dementia.

Blennow K, Davidsson P, Wallin A, Gottfries CG, Svennerholm L. Blennow K, et al. Int Psychogeriatr. 1994 Spring;6(1):13-22; discussion 59-60. doi: 10.1017/s1041610294001584. Int Psychogeriatr. 1994. PMID: 8054491

5

Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?

Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. Blennow K, et al. Mol Chem Neuropathol. 1995 Dec;26(3):231-45. doi: 10.1007/BF02815140. Mol Chem Neuropathol. 1995. PMID: 8748926

6

The neurochemistry of Alzheimer's disease.

Blennow K, Cowburn RF. Blennow K, et al. Acta Neurol Scand Suppl. 1996;168:77-86. doi: 10.1111/j.1600-0404.1996.tb00378.x. Acta Neurol Scand Suppl. 1996. PMID: 8997425 Review.

7

The apolipoprotein E epsilon4 allele frequency is normal in fronto-temporal dementia, but correlates with age at onset of disease.

Minthon L, Hesse C, Sjögren M, Englund E, Gustafson L, Blennow K. Minthon L, et al. Among authors: blennow k. Neurosci Lett. 1997 Apr 18;226(1):65-7. doi: 10.1016/s0304-3940(97)00230-9. Neurosci Lett. 1997. PMID: 9153643

8

Combination of the different biological markers for increasing specificity of in vivo Alzheimer's testing.

Blennow K, Vanmechelen E. Blennow K, et al. J Neural Transm Suppl. 1998;53:223-35. doi: 10.1007/978-3-7091-6467-9_20. J Neural Transm Suppl. 1998. PMID: 9700660 Review.

9

Decreased monoamine metabolites in frontotemporal dementia and Alzheimer's disease.

Sjögren M, Minthon L, Passant U, Blennow K, Wallin A. Sjögren M, et al. Among authors: blennow k. Neurobiol Aging. 1998 Sep-Oct;19(5):379-84. doi: 10.1016/s0197-4580(98)00086-4. Neurobiol Aging. 1998. PMID: 9880039

10

Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease.

Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, Vanderstichele H, Vanmechelen E, Blennow K. Andreasen N, et al. Among authors: blennow k. Arch Neurol. 1999 Jun;56(6):673-80. doi: 10.1001/archneur.56.6.673. Arch Neurol. 1999. PMID: 10369305

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,084 results

Search Page